Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go.

@article{Firmann2010PrevalenceTA,
  title={Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go.},
  author={Mathieu Firmann and Pedro M. Marques-Vidal and Fred Paccaud and Vincent E. Mooser and Nicolas Rodondi and G{\'e}rard Waeber and Peter Vollenweider},
  journal={European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology},
  year={2010},
  volume={17 6},
  pages={682-7}
}
BACKGROUND There is little information regarding the prevalence and management of dyslipidaemia in Switzerland. DESIGN Cross-sectional population-based study of 3238 women and 2846 men aged 35-75. METHODS Dyslipidaemia prevalence, treatment and control were defined according to PROCAM guidelines adapted to Switzerland. RESULTS About 29% of the overall sample presented with dyslipidaemia, of which 39% were treated and 58% of those treated were controlled. Among the 710 patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Comment mettre en application des recommandations de pratique clinique ? L ’ exemple des dyslipidémies [ How to apply clinical guidelines in medical practice ? The example of dyslipidemia ]

  • N Rodondi, T Peng, AJ Karter, DC Bauer, E Vittinghoff, S Tang
  • Rev Med Suisse
  • 2008

Guidelines, défis et dépits. Enquéte sur la prise en charge

  • M Burnier, G. Noll
  • metabolic syndrome. BMC Cardiovasc Disord
  • 2008

Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom

  • N Rodondi, J Cornuz, P Marques-Vidal, J Butler, D Hayoz, A Pecoud
  • Br J Clin Pharmacol
  • 2008

Similar Papers

Loading similar papers…